Federated Investors Inc. PA Acquires 7,327 Shares of PerkinElmer, Inc. (PKI)
Federated Investors Inc. PA boosted its holdings in shares of PerkinElmer, Inc. (NYSE:PKI) by 164.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,787 shares of the medical research company’s stock after buying an additional 7,327 shares during the period. Federated Investors Inc. PA’s holdings in PerkinElmer were worth $803,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the business. Boston Private Wealth LLC boosted its stake in PerkinElmer by 13.9% during the second quarter. Boston Private Wealth LLC now owns 12,230 shares of the medical research company’s stock worth $833,000 after buying an additional 1,494 shares in the last quarter. Marshall Wace North America L.P. boosted its stake in PerkinElmer by 32.0% during the second quarter. Marshall Wace North America L.P. now owns 152,102 shares of the medical research company’s stock worth $10,342,000 after buying an additional 36,916 shares in the last quarter. Blair William & Co. IL acquired a new stake in PerkinElmer during the second quarter worth $577,000. Legal & General Group Plc boosted its stake in PerkinElmer by 13.0% during the second quarter. Legal & General Group Plc now owns 100,010 shares of the medical research company’s stock worth $6,815,000 after buying an additional 11,530 shares in the last quarter. Finally, Denver Investment Advisors LLC acquired a new stake in PerkinElmer during the second quarter worth $1,475,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Federated Investors Inc. PA Acquires 7,327 Shares of PerkinElmer, Inc. (PKI)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/federated-investors-inc-pa-acquires-7327-shares-of-perkinelmer-inc-pki/1570160.html.
A number of equities research analysts have weighed in on PKI shares. BidaskClub downgraded shares of PerkinElmer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. Cantor Fitzgerald set a $65.00 price target on shares of PerkinElmer and gave the stock a “hold” rating in a research note on Monday, June 19th. Cowen and Company reiterated a “market perform” rating and set a $70.00 price target (up previously from $61.00) on shares of PerkinElmer in a research note on Tuesday, June 20th. Jefferies Group LLC reiterated a “hold” rating and set a $69.00 price target (up previously from $58.00) on shares of PerkinElmer in a research note on Tuesday, June 20th. Finally, Evercore ISI reiterated an “in-line” rating and set a $68.00 price target (up previously from $62.50) on shares of PerkinElmer in a research note on Thursday, June 22nd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the stock. PerkinElmer currently has a consensus rating of “Hold” and a consensus target price of $67.00.
PerkinElmer, Inc. (NYSE PKI) opened at 69.08 on Monday. PerkinElmer, Inc. has a one year low of $45.35 and a one year high of $70.16. The firm’s 50 day moving average price is $65.89 and its 200-day moving average price is $62.89. The company has a market capitalization of $7.61 billion, a PE ratio of 20.83 and a beta of 0.74.
PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $547.00 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. PerkinElmer’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. Equities analysts forecast that PerkinElmer, Inc. will post $2.89 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is currently 8.46%.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.